| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 2 securities · may seek to influence control | ||||||
|
Rallybio Corp
13D/A
RLYB · 75120L209
|
0% |
5/6/2026
Event 5/4/2026
|
||||
| 5AM Ventures V, L.P. | 0% | |||||
| 5AM Partners V, LLC | 0% | |||||
| 5AM Opportunities I, L.P. | 0% | |||||
| 5AM Opportunities I (GP), LLC | 0% | |||||
| Andrew J. Schwab | 0% | |||||
| Kush Parmar | 0% | |||||
| Scott M. Rocklage | 0% | |||||
|
Entrada Therapeutics, Inc.
13D/A
TRDA · 29384C108
|
10.8% |
11/18/2025
Event 11/14/2025
|
||||
| 5AM Ventures V, L.P. | 7.8% | |||||
| 5AM Partners V, LLC | 7.8% | |||||
| 5AM Opportunities I, L.P. | 2.9% | |||||
| 5AM Opportunities I (GP), LLC | 2.9% | |||||
| Andrew J. Schwab | 10.6% | |||||
| Kush Parmar | 10.8% | |||||
| Scott M. Rocklage | 7.8% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.